Novo Nordisk has money to spend on M&A after losing the bidding war for obesity drugmaker Metsera, CEO Mike Doustdar told attendees Tuesday at the JPMorgan Healthcare Conference.
Why it matters: The Danish drug giant is one of several pharma companies open to acquisitions this year — a positive sign for biotech.
